AGIO · Agios Pharmaceuticals

The thesis

Agios Pharmaceuticals' shares are more likely to lag the S&P 500 over the next three months. The Food and Drug Administration (FDA) now decides mitapivat in sickle cell disease by 1 February 2027, and that ruling, with any safety program attached, settles the case. Thalassemia sales are growing, but new US prescriptions are slowing and the sickle cell label is unresolved.

The original case rested on approval by 1 November 2026. Agios said on 30 October 2026 that the FDA had extended its review by three months after classing the company's 19 October 2026 reply as a major amendment. The shares fell 9.9% on 5 November 2026, the day of the Q3 report, to a close of $28.27. They closed at $32.82 on 11 November 2026, above the 200-day average of $31.81 and below the 50-day average of $33.17.

At $32.82 the shares sit 28.7% below the 52-week intraday high of $46.00 (18 November 2025). In this view the market is pricing approval as likely but a delayed launch with a safety program as a real possibility.

Bullish and bearish views on Agios Pharmaceuticals, Inc.

The bull case on Agios Pharmaceuticals, Inc. (AGIO), in brief: US sales grew 20% in a quarter. The bear case: the FDA raised a safety question late.

Bull case

• US sales grew 20% in a quarter. Agios reported Q3 2026 US mitapivat revenue of $48.7 million, up from $40.9 million in Q2 (5 November 2026 results). Worldwide revenue was $55.4 million against $12.9 million a year earlier.
• Patients stay on therapy. Agios counted 619 US AQVESME prescriptions with completed start forms at 30 September 2026, with 48 more in process. About 75% of patients remained on therapy after six months (5 November 2026 results).
• Label talks are under way. Agios said on 30 October 2026 that labeling discussions with the FDA continue and that it is launch-ready. Its updated safety figures through 9 October 2026 showed no liver injury in sickle cell patients resembling the pattern seen in thalassemia trials.
• Analysts still see upside. H.C. Wainwright raised its target to $62 with a Buy rating on 6 November 2026. BofA Securities' target is $48, down from $50 (7 November 2026). Truist rates the shares Buy with a target of $35, lowered on 6 November 2026.
• Cash is large and costs are falling. Agios held $907.0 million of cash and marketable securities at 30 September 2026. It is cutting more than 100 research roles by year-end and targets non-GAAP profitability in 2028 (5 November 2026 results).
• Conference data arrive before the decision. Agios has 14 abstracts at the American Society of Hematology meeting on 12 December to 15 December 2026, including an oral presentation of long-term RISE UP hemoglobin results.

Bear case

• The FDA raised a safety question late. It asked on 9 October 2026 whether a Risk Evaluation and Mitigation Strategy (REMS), a mandatory safety program, is needed. It classed the 19 October 2026 response as a major amendment on 28 October 2026. J.P. Morgan's Tessa Romero said the delay could signal a more cautious FDA, per Genetic Engineering & Biotechnology News.
• New thalassemia prescriptions are slowing. Completed start forms were 242 in Q1, 200 in Q2 and 177 in Q3 2026, per a Finviz summary of the Q3 report. The same summary says Agios will stop reporting that figure.
• The pain-crisis endpoint missed significance. RISE UP results in The Lancet showed 2.6 annualized pain crises on mitapivat against 3.1 on placebo (p=0.1213). Hemoglobin response was 41% against 3%, so approval depends on how the FDA weighs a hemoglobin measure.
• Precedent cuts against hemoglobin approvals. Global Blood Therapeutics' Oxbryta won sickle cell approval on a hemoglobin measure and was withdrawn on safety grounds in 2024.
• A competitor gains time. Novo Nordisk's etavopivat, an oral drug of the same class, met both Phase 3 co-primary endpoints on 20 April 2026. Genetic Engineering & Biotechnology News expects its first filing in Q4 2026.
• The company still loses money. The Q3 2026 net loss was $65.0 million, and cash fell from $1.16 billion at 31 December 2025 to $907.0 million at 30 September 2026 (5 November 2026 results). No 2027 financial guidance was reported, per the Finviz summary.

Price setup

The shares closed at $31.38 on 4 November 2026, $28.27 on 5 November 2026, $29.41 on 6 November 2026 and $31.38 on 9 November 2026. They rose to $31.76 on 10 November 2026 and $32.82 on 11 November 2026. The 3-month change is −1.9%, against a close of $33.47 on 13 August 2026.

The 52-week closing low is $22.34 (19 November 2025). The 50-day average of $33.17 is the nearest level above the last close. The shares traded near $37.5 to $37.7 in late October, before the review extension.

Insider sales came before the extension. Chief Medical Officer Sarah Gheuens sold 1,989 shares at an average of $37.53 on 21 October to 22 October 2026 and 7,866 shares at $37.69 on 26 October 2026, both under Rule 10b5-1 plans, per SEC Form 4 filings.

Catalysts ahead

• 12 December 2026: American Society of Hematology meeting opens in New Orleans and runs through 15 December 2026; Agios presents long-term RISE UP hemoglobin results in an oral session on 12 December 2026. Longer-term efficacy and safety results arrive before the FDA decision, in the area the agency has questioned.
• 14 December 2026: Agios virtual investor event during the ASH meeting. Management may address the sickle cell label, safety program and launch plans before the FDA decision.
• ~31 December 2026 (est.): Novo Nordisk's first regulatory filing for etavopivat in sickle cell disease, expected in Q4 2026. A filing shows how much of mitapivat's lead in the same patient group remains after the three-month delay.
• 1 February 2027: FDA goal date for mitapivat in sickle cell disease. Settles whether the drug wins its third US indication and whether a REMS safety program comes with it.

What would change the view

A daily close above $38.12, the highest close of the last 20 sessions before the 30 October 2026 review extension, which would show the shares leading the S&P 500 again. A raised 2027 outlook or an FDA approval without a safety program would point the same way.

What it trades with

The shares move mainly on company-specific regulatory news. They rose about 15% on the 7 July 2026 Priority Review, per Benzinga, and fell nearly 18% on the 30 October 2026 extension, per Genetic Engineering & Biotechnology News. Etavopivat news matters directly because both drugs target the same patients through the same mechanism.